Drugs / SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04742595 | Dec 2020 → Sep 2024 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04742595 ↗ |
| Action | Deplete | “are designed to kill cells infected with SARS-CoV-2 virus” NCT04742595 ↗ |
| Route | Intravenous | “Given IV” NCT04742595 ↗ |